Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

11.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K
RNA Splicing01:32

RNA Splicing

56.9K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA methylation in kidney disorders: Insights into molecular machinery and therapeutic opportunities.

Cellular signalling·2026
Same author

The effect of TIM1<sup>+</sup> Breg cells in myocardial ischemia-reperfusion injury.

Cell death discovery·2025
Same author

Resident Macrophage-Orchestrated Immune and Fibroblast Interactions in Immune Checkpoint Inhibitor-Associated Nephrotoxicity.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Decoding m<sup>6</sup>A RNA methylation in kidney disorders: from molecular insights to therapeutic strategies.

Journal of translational medicine·2025
Same author

The F-box protein SlSAP1 and SlSAP2 redundantly control leaf and fruit size by modulating the stability of SlKIX8 and SlKIX9 in tomato.

The New phytologist·2025
Same author

Senescence-induced p21<sup>high</sup> macrophages contributed to CD8<sup>+</sup> T cells-related immune hyporesponsiveness in kidney transplantation via Zfp36/IL-27 axis.

Cell discovery·2025

Related Experiment Video

Updated: Sep 10, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

635

Long non-coding RNA NR2F1-AS1: an increasingly significant LncRNA in human cancers.

Qinfan Yao1,2,3,4,5, Xinyi Zhang1,2,3,4,5, Yitong Chen1,2,3,4,5

  • 1Kidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79, Hangzhou, 310003, China.

Journal of Physiology and Biochemistry
|August 19, 2025
PubMed
Summary

Long non-coding RNAs (lncRNAs) like NR2F1-AS1 are key in cancer. This review details NR2F1-AS1

Keywords:
CancerClinical applicationFunctionLncRNANR2F1-AS1

More Related Videos

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

1.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Related Experiment Videos

Last Updated: Sep 10, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

635
Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

1.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) regulate cellular processes.
  • NR2F1-AS1 is a lncRNA with altered expression in various cancers.
  • Its role in tumorigenesis is increasingly recognized.

Purpose of the Study:

  • To review the expression patterns and prognostic significance of NR2F1-AS1.
  • To elucidate the biological functions and molecular mechanisms of NR2F1-AS1 in cancer.
  • To highlight NR2F1-AS1 as a potential cancer biomarker and therapeutic target.

Main Methods:

  • Literature review of studies on NR2F1-AS1 in human cancers.
  • Analysis of expression data and clinicopathological correlations.
  • Synthesis of findings on molecular mechanisms and biological roles.

Main Results:

  • NR2F1-AS1 exhibits aberrant expression across multiple cancer types.
  • Its function is context-dependent, acting as an oncogene or tumor suppressor.
  • NR2F1-AS1 influences cancer via signaling pathways, gene regulation, and molecular interactions.

Conclusions:

  • NR2F1-AS1 is a significant player in cancer development and progression.
  • Its context-specific roles suggest potential as a biomarker and therapeutic target.
  • Further research is warranted to fully understand and utilize NR2F1-AS1 in oncology.